Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05108220 |
Other study ID # |
Pro00054510 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
October 15, 2020 |
Est. completion date |
December 30, 2020 |
Study information
Verified date |
October 2021 |
Source |
Radicle Science |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The investigators will conduct a retrospective cohort analysis of a consumer trial conducted
by Rae Wellness. The trial took place between October 15, 2020 and December 30, 2020 and
involved 1350 U.S. women who used in-home use tests (IHUT) of various Cannabidiol (CBD)
products. Participants were randomized to one of 9 groups: 8 groups received one of 8
different CBD products in the mail, and one group served as the control and did not consume
any CBD product. The CBD products varied by method of delivery, concentration of
Tetrahydrocannabinol (THC), and dosage of CBD. Participants were asked to use the product
once daily for 60 day and to complete health questionnaires at baseline, 30 days and 60 days.
Description:
Between October 1-7, 2020, women from across the US were recruited by Rae Wellness to
participate in a 60-day in-home use test (IHUT) of various Cannabidiol (CBD) products. The
inclusion criteria were: women; between the ages of 24-44; reported symptoms associated with
at least 4 out of 6 health issues (stress; anxiety; pain; sleep issues; digestive issues; low
libido). Individuals were excluded if they were pregnant or breastfeeding. 1,350 women were
randomly selected to participate in the study. The participants were randomized to one of 9
groups in the IHUT (150 in each group): 8 groups received one of 8 different CBD products in
the mail, and one group served as the control and did not consume any CBD product. The CBD
products varied by method of delivery (oil or capsule), concentration of Tetrahydrocannabinol
(THC; less than 0.3% THC or 0% THC), and dosage of CBD (15, 20, 25 and 30 mg). Participants
were asked to use the product once daily every day for 60 consecutive days, and to complete a
health questionnaire online on 3 occasions: before initiating the product (baseline), 30 days
after initiating the product, and 60 days after initiating the product. Those in the control
group were also asked to complete the health questionnaire at each time point but did not
receive nor consume any CBD product. The health questionnaire assessed anxiety, physical
health, digestive health, sleep patterns, general wellness and sexual satisfaction using
questions drawn from validated health indices.